May 29 |
Nurix Therapeutics to Participate in the Jefferies Global Healthcare Conference
|
May 28 |
Nurix Therapeutics appoints Paula O’Connor as chief medical officer
|
May 28 |
Nurix Therapeutics Appoints Paula G. O’Connor, M.D., as Chief Medical Officer and Pasit Phiasivongsa, Ph.D., as Chief Technical Officer
|
May 20 |
Nurix Therapeutics announces Julia P. Gregory as new board Chair
|
May 20 |
Nurix Therapeutics Announces Board Chair Transition
|
May 20 |
Nurix Therapeutics (NRIX) Moves 7.7% Higher: Will This Strength Last?
|
May 14 |
Nurix Therapeutics Announces Upcoming Oral Presentation of New Data from Ongoing Clinical Trial of NX-5948, a Selective Bruton’s Tyrosine Kinase (BTK) Degrader, at the European Hematology Association Congress (EHA2024)
|
May 7 |
Nurix Therapeutics to Participate in RBC Capital Markets Global Healthcare Conference
|
Apr 16 |
Nurix Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
|
Apr 15 |
Roche's (RHHBY) Combination Therapy Meets Goal in Lymphoma Study
|